SOURCE: OxySure Systems, Inc.

OxySure Systems, Inc.

SOURCE: Cardiac Science Corporation

Cardiac Science Corporation

July 21, 2015 08:30 ET

OxySure Systems (OXYS) Teams Up With Cardiac Science

Initiatives Include AEDs for Special Olympics Support

FRISCO, TX and WAUKESHA, WI--(Marketwired - July 21, 2015) - OxySure Systems, Inc. (OTCQB: OXYS) (OxySure, or the Company), the medical device innovator of life-saving easy-to-use emergency oxygen solutions with its "oxygen from powder" technology, and Cardiac Science Corporation (Cardiac Science), a market-leading manufacturer and marketer of automated external defibrillators (AEDs) and related services today announced a partnership covering various joint strategic initiatives.

Cardiac Science will supply twenty five (25) of its Powerheart®G3 Plus AEDs to OxySure to support the Special Olympics World Games, taking place July 25-August 2 in Los Angeles. In its role as a Champion of the World Games, OxySure will support World Games participants and attendees, providing AEDs, OxySure Model 615 units, and OxySure Pulse Oximeters to the 27 Venues, Fields of Play, Spectator First Aid tents, and overnight nursing staff.

Additionally, Cardiac Science and OxySure will jointly support the recently established Kylee Shea Miracle Foundation, founded in honor of cardiac arrest survivor Kylee Shea. OxySure is also a Gold Level Partner of Cardiac Science.

Speaking at a joint sales launch of the new Cardiac Science Powerheart®G5 AED in Frisco, Texas, recently, Clark Hood, Vice President of Resuscitation Sales for OxySure, stated: "We are pleased with the mutual cooperation we have enjoyed with Cardiac Science so far; and we look forward to the continued strengthening of this relationship as we market and sell our lifesaving products together."

The recently launched Cardiac Science Powerheart®G5 AED is the most advanced Cardiac Science AED to date, and first-time rescuers will benefit from the Powerheart G5's RescueCoach™ user-paced instruction, intuitive pad design, and automatic shock delivery to reduce the likelihood of human error.

Said Al Ford, Cardiac Science General Manager and Senior Vice President of Sales / Marketing: "We are excited about our relationship with OxySure. The OxySure Model 615 is a great companion product to our AEDs, and we intend to work together closely to address the significant market need to improve outcomes in sudden cardiac arrest, which is the nation's No. 1 killer, claiming approximately 369,000 lives every year.1"

1. According to American Heart Association.

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from two dry, inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments.

About Cardiac Science Corporation

Cardiac Science is a global leader in the development, manufacture, and marketing of life-saving AED devices providing assistance to SCA victims worldwide. Cardiac Science extends lives by providing the public and healthcare professionals with life-saving devices. We are committed to eliminating needless delays between sudden cardiac arrest (SCA) and life-saving defibrillation by ensuring automated external defibrillators (AEDs) are accessible and simple to use. Our innovative, patented Powerheart AEDs provide assistance to SCA victims in all walks of life. Headquartered in Waukesha, Wisconsin, just west of Milwaukee, the company also has a manufacturing facility in Deerfield, Wisconsin, as well as operations in California, Denmark, France, Italy, and the United Kingdom. For information, visit

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

The following files are available for download:

Contact Information